Free Trial

Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

+0.01 (+2.48%)
(As of 05/29/2024 ET)
Today's Range
50-Day Range
52-Week Range
46,015 shs
Average Volume
325,937 shs
Market Capitalization
$6.60 million
P/E Ratio
Dividend Yield
Price Target

Cadrenal Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
748.5% Upside
$3.50 Price Target
Short Interest
0.12% of Float Sold Short
Dividend Strength
News Sentiment
1.19mentions of Cadrenal Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.34) to ($0.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

CVKD stock logo

About Cadrenal Therapeutics Stock (NASDAQ:CVKD)

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

CVKD Stock Price History

CVKD Stock News Headlines

Cadrenal Therapeutics Inc CVKD
Cadrenal Therapeutics, Inc. (CVKD)
See More Headlines
Receive CVKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.39 per share


Free Float
Market Cap
$6.40 million
Not Optionable
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Quang X. Pham (Age 59)
    Chairman & CEO
    Comp: $967k
  • Mr. Matthew K. Szot CPA (Age 50)
    CPA, Chief Financial Officer
    Comp: $594.89k
  • Dr. Douglas W. Losordo FACC (Age 66)
    FAHA, M.D., Chief Medical Officer
    Comp: $528.69k
  • Mr. Jeffrey Cole
    Chief Operating Officer

CVKD Stock Analysis - Frequently Asked Questions

Should I buy or sell Cadrenal Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVKD shares.
View CVKD analyst ratings
or view top-rated stocks.

What is Cadrenal Therapeutics' stock price target for 2024?

2 brokers have issued 12-month price objectives for Cadrenal Therapeutics' shares. Their CVKD share price targets range from $3.00 to $4.00. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 748.5% from the stock's current price.
View analysts price targets for CVKD
or view top-rated stocks among Wall Street analysts.

How have CVKD shares performed in 2024?

Cadrenal Therapeutics' stock was trading at $0.7399 at the beginning of the year. Since then, CVKD stock has decreased by 44.2% and is now trading at $0.4125.
View the best growth stocks for 2024 here

Are investors shorting Cadrenal Therapeutics?

Cadrenal Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 10,000 shares, a decrease of 85.4% from the April 30th total of 68,500 shares. Based on an average daily volume of 228,400 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company's shares are short sold.
View Cadrenal Therapeutics' Short Interest

When is Cadrenal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our CVKD earnings forecast

How were Cadrenal Therapeutics' earnings last quarter?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04.

When did Cadrenal Therapeutics IPO?

Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering (IPO) on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share.

How do I buy shares of Cadrenal Therapeutics?

Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVKD) was last updated on 5/29/2024 by Staff

From Our Partners